Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pritelivir vs Valacyclovir for Genital HSV Shedding
NCT01658826Phase 2Terminated
- Sponsor
- AiCuris
- Start
- Oct 2012
- Primary completion
- May 2013
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pritelivir in genital herpes (2 arms), sponsored by AiCuris. Primary endpoints: Within-subject Genital HSV Mucocutaneous Shedding Rate at 28 days and Overall Shedding Rate at 28 days. Started Oct 2012; status: terminated.
02
Drugs
pritelivir
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT01658826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01658826.